Table 2 Multivariate analysis of risk factors for acute kidney injury, mortality and unfavourable neurological outcome in resuscitated, comatose out-of-hospital cardiac arrest patients

 Model I

Witnessed CA^c

No/yes

2.27 (0.85–6.07)

0.104

0.747 (0.667-0.817)

0.719 (0.649-0.790)

0.084

 (n = 195)

SOFA score day 0

≥/<10

3.08 (1.46–6.48)

0.003

Urea day 0

≥/<6.7 mmol/L

2.63 (1.40–4.95)

0.003

Admission cystatin C

≥/<291/ng/mL

2.42 (2.29–4.54)

0.006

 Model II

Witnessed CA^c

No/yes

2.15 (0.80–5.77)

0.128

0.752 (0.682-0.821)

0.719 (0.649-0.790

0.046

 (n = 195)

SOFA score day 0

≥/<10

2.94 (1.39–6.21)

0.005

Urea day 0

≥/<6.7 mmol/L

2.63 (1.40–4.95)

0.003

Admission NGAL

≥/<219 ng/mL

2.59 (1.37–4.89)

0.004

 Model III

SOFA score day 0

≥/<10

2.76 (1.25–6.10)

0.012

0.725 (0.644-0.806)

 (n = 164)

Urea day 0

≥/<6.7 mmol/L

1.98 (1.00–3.93)

0.049

Cystatin C day 3

≥/<59 ng/mL

2.87 (1.45–5.70)

0.003

 Model IV

SOFA score day 0

≥/<10

2.83 (1.24–6.50)

0.014

0.774 (0.700-0.848)

 (n = 164)

Urea day 0

≥/<6.7 mmol/L

2.82 (1.12–4.66)

0.024

NGAL day 3

≥/<110 ng/mL

5.46 (2.65–11.24)

<0.001

 Model V

Initial VT/VF^c

No/yes

4.70 (2.27–9.74)

<0.001

0.811 (0.751-0.872)

0.790 (0.727-0.852)

0.141

 (n = 195)

AKI within 3 days

Yes/no

2.83 (1.40–5.69)

0.004

SOFA sore day 0

≥/<10

3.40 (1.47–7.88)

0.004

Admission cystatin C

≥/<291 ng/mL

2.88 (1.44–5.77)

0.003

 Model VI

Initial VT/VF^c

No/yes

4.11 (1.99–8.53)

<0.001

0.812 (0.751-0.873)

0.790 (0.727-0.852)

0.131

 (n = 195)

AKI within 3 days

Yes/no

2.86 (1.43–5.74)

0.003

SOFA sore day 0

≥/<10

3.28 (1.43–7.50)

0.005

Admission NGAL

≥/<219 ng/mL

2.87 (1.44–5.72)

0.003

 Model VII

Initial VT/VF^c

No/yes

3.13 (1.45–6.72)

0.004

0.784 (0.713-0.854)

 (n = 164)

AKI within 3 days

Yes/no

2.44 (1.16–5.13)

0.019

SOFA sore day 0

≥/<10

2.67 (1.14–6.23)

0.024

Cystatin C day 3

≥/<59 ng/mL

2.45 (1.17–5.13)

0.018

 Model VIII

Initial VT/VF^c

No/yes

3.12 (1.45–6.69)

0.004

0.785 (0.713-0.857)

 (n = 164)

AKI within 3 days

Yes/no

2.06 (0.95–4.47)

0.069

SOFA score day 0

≥/<10

2.88 (1.22–6.84)

0.016

NGAL day 3

≥/<110 ng/mL

2.85 (1.32–6.14)

0.008

 Model IX

Initial VT/VF^c

No/yes

5.07 (2.40–10.74)

<0.001

0.819 (0.759-0.878)

0.810 (0.750-0.870)

0.264

 (n = 195)

AKI within 3 days

Yes/no

2.67 (1.32–5.40)

0.006

BE day 0

</≥–7 mmol/L

2.07 (1.00–4.26)

0.050

SOFA score day 0

≥/<10

2.45 (1.08–5.57)

0.032

Admission cystatin C

≥/<291 ng/mL

2.06 (1.00–4.25)

0.050

 Model X^b

Initial VT/VF^c

No/yes

4.92 (2.35–10.38)

<0.001

0.810 (0.750-0.871)

 (n = 195)

AKI within 3 days

Yes/no

3.03 (1.52–6.02)

0.002

BE day 0

</≥–7 mmol/L

2.56 (1.29–5.09)

0.007

SOFA score day 0

≥/<10

2.48 (1.11–5.54)

0.027

 Model XI

Initial VT/VF^c

No/yes

3.42 (1.58–7.39)

0.002

0.778 (0.707-0.849)

 (n = 164)

AKI within 3 days

Yes/no

2.45 (1.17–5.12)

0.017

BE day 0

</≥–7 mmol/L

2.53 (1.24–5.18)

0.011

Cystatin C day 3

≥/<59 ng/mL

2.25 (1.09–4.65)

0.029

 Model XII

Initial VT/VF^c

No/yes

3.77 (1.69–8.38)

0.001

0.797 (0.729-0.866)

 (n = 164)

Fluid balance day 0

≥/<4.45 L/day

2.12 (1.05–4.66)

0.037

Urea day 0

≥/<6.7 mmol/L

2.13 (1.03–4.43)

0.043

BE day 0

</≥–7 mmol/L

2.21 (1.06–4.62)

0.035

NGAL day 3

≥/<110 ng/mL

3.41 (1.65–7.06)

0.001